Precision BioSciences Inc (DTIL)

[NY1972]

NVS CART T needs a charge soon. Selling a salvage therapy seems to be the only viable option near term.

YTB323, an investigational, autologous CD19-directed CAR-T cell therapy developed using the T-Charge platform, showed promising results in the diffuse large B-cell lymphoma arm of a first-in-human, multicenter, Phase I dose-escalation study. Patients received a single treatment of YTB323 at two dose levels (DL). The median administered doses were 2.5×106 CAR+ cells (DL1; n=4)